No Data
No Data
Passage Bio (PASG) Gets a Buy From TD Cowen
Passage Bio | 10-Q: Quarterly report
Passage Bio Unveils Updated Corporate Presentation
Passage Bio: Cash Runway Into 4Q 2025 >PASG
Passage Bio: Cash Runway Into 4Q 2025 >PASG
Passage Bio 1Q Loss/Shr 30c >PASG
Passage Bio 1Q Loss/Shr 30c >PASG
Passage Bio to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
PHILADELPHIA, April 22, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced